Study identifier:D7960C00006
ClinicalTrials.gov identifier:NCT06173570
EudraCT identifier:N/A
CTIS identifier:2023-506197-12-00
A Phase IIb, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AZD0780 in Participants with Dyslipidemia
Dyslipidemia
Phase 2
No
AZD0780, Placebo
All
428
Interventional
18 Years - 75 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Oct 2024 by AstraZeneca
AstraZeneca
AstraZeneca K.K.
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Arm A AZD0780, Dose 1 | Drug: AZD0780 AZD0780 administered orally, once daily for 12 weeks |
Experimental: Arm B AZD0780, Dose 2 | Drug: AZD0780 AZD0780 administered orally, once daily for 12 weeks |
Experimental: Arm C AZD0780, Dose 3 | Drug: AZD0780 AZD0780 administered orally, once daily for 12 weeks |
Experimental: Arm D AZD0780, Dose 4 | Drug: AZD0780 AZD0780 administered orally, once daily for 12 weeks |
Placebo Comparator: Arm E Placebo, matched for appearance | Drug: Placebo Placebo administered orally, once daily for 12 weeks |